← All candidates
Two insiders bought $1.67M in two days.
22 filings on record.
RLMDRELMADA THERAPEUTICS, INC.
NasdaqCM · Healthcare · $457.61M
$4.44
+0.00% · Sep 15
Two insiders bought $1.67M in two days.
Led by Shenouda Maged, chief financial officer.
Price · 1Y · daily● 10 buys◆ 11 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
Reverse-split 2×. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what RLMD ever actually traded at. The drop is real, but those huge old numbers aren't.
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$457.61M
Float
77.8M
73% public
Short % float
Pro
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
Chief Financial Officer
Shenouda Maged
Bought $1.10M on Nov 5 — 500,000 sh @ $2.20, held direct, 63% of their stake.
1 of 1 position beat the S&P
Chief Executive Officer
Traversa Sergio
Bought $599.5K on Nov 5 — 272,500 sh @ $2.20, held direct, 21% of their stake.
1 of 1 position beat the S&P
CAO and COO
Ence Chuck
Bought $299.2K on Nov 5 — 136,000 sh @ $2.20, held direct, 34% of their stake.
1 of 1 position beat the S&P
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
1 filingnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
8 more transactions on Pro →Context
Wall St
$12.40 avg target
+179.3% vs today · 5 analysts · consensus Strong Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
1 of 3 quarters beat
Q2 '26−$0.11 act+$0.09
Q4 '25−$0.29 act−$0.15
Q3 '25−$0.30 act
Coverage
After Plunging 18.5% in 4 Weeks, Here's Why the Trend Might Reverse for Relmada Therapeutics (RLMD)Zacks · 2w agoHere's Why Relmada Therapeutics (RLMD) Is a Great 'Buy the Bottom' Stock NowZacks · 3w agoDown 29.6% in 4 Weeks, Here's Why Relmada Therapeutics (RLMD) Looks Ripe for a TurnaroundZacks · 08-11Relmada Therapeutics Q2 Earnings Call HighlightsMarketBeat · 08-07
The file stays open
22 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice